Cargando…
Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds
The pivotal role of cancer stem cells (CSCs) in the initiation and progression of malignancies has been rigorously validated, and the specific methods for identifying and isolating the CSCs from the parental cancer population have also been rapidly developed in recent years. This review aims to prov...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926427/ https://www.ncbi.nlm.nih.gov/pubmed/27338343 http://dx.doi.org/10.3390/ijms17060893 |
_version_ | 1782440110518697984 |
---|---|
author | Hong, Ming Tan, Hor Yue Li, Sha Cheung, Fan Wang, Ning Nagamatsu, Tadashi Feng, Yibin |
author_facet | Hong, Ming Tan, Hor Yue Li, Sha Cheung, Fan Wang, Ning Nagamatsu, Tadashi Feng, Yibin |
author_sort | Hong, Ming |
collection | PubMed |
description | The pivotal role of cancer stem cells (CSCs) in the initiation and progression of malignancies has been rigorously validated, and the specific methods for identifying and isolating the CSCs from the parental cancer population have also been rapidly developed in recent years. This review aims to provide an overview of recent research progress of Chinese medicines (CMs) and their active compounds in inhibiting tumor progression by targeting CSCs. A great deal of CMs and their active compounds, such as Antrodia camphorate, berberine, resveratrol, and curcumin have been shown to regress CSCs, in terms of reversing drug resistance, inducing cell death and inhibiting cell proliferation as well as metastasis. Furthermore, one of the active compounds in coptis, berbamine may inhibit tumor progression by modulating microRNAs to regulate CSCs. The underlying molecular mechanisms and related signaling pathways involved in these processes were also discussed and concluded in this paper. Overall, the use of CMs and their active compounds may be a promising therapeutic strategy to eradicate cancer by targeting CSCs. However, further studies are needed to clarify the potential of clinical application of CMs and their active compounds as complementary and alternative therapy in this field. |
format | Online Article Text |
id | pubmed-4926427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-49264272016-07-06 Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds Hong, Ming Tan, Hor Yue Li, Sha Cheung, Fan Wang, Ning Nagamatsu, Tadashi Feng, Yibin Int J Mol Sci Review The pivotal role of cancer stem cells (CSCs) in the initiation and progression of malignancies has been rigorously validated, and the specific methods for identifying and isolating the CSCs from the parental cancer population have also been rapidly developed in recent years. This review aims to provide an overview of recent research progress of Chinese medicines (CMs) and their active compounds in inhibiting tumor progression by targeting CSCs. A great deal of CMs and their active compounds, such as Antrodia camphorate, berberine, resveratrol, and curcumin have been shown to regress CSCs, in terms of reversing drug resistance, inducing cell death and inhibiting cell proliferation as well as metastasis. Furthermore, one of the active compounds in coptis, berbamine may inhibit tumor progression by modulating microRNAs to regulate CSCs. The underlying molecular mechanisms and related signaling pathways involved in these processes were also discussed and concluded in this paper. Overall, the use of CMs and their active compounds may be a promising therapeutic strategy to eradicate cancer by targeting CSCs. However, further studies are needed to clarify the potential of clinical application of CMs and their active compounds as complementary and alternative therapy in this field. MDPI 2016-06-07 /pmc/articles/PMC4926427/ /pubmed/27338343 http://dx.doi.org/10.3390/ijms17060893 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hong, Ming Tan, Hor Yue Li, Sha Cheung, Fan Wang, Ning Nagamatsu, Tadashi Feng, Yibin Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds |
title | Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds |
title_full | Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds |
title_fullStr | Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds |
title_full_unstemmed | Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds |
title_short | Cancer Stem Cells: The Potential Targets of Chinese Medicines and Their Active Compounds |
title_sort | cancer stem cells: the potential targets of chinese medicines and their active compounds |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926427/ https://www.ncbi.nlm.nih.gov/pubmed/27338343 http://dx.doi.org/10.3390/ijms17060893 |
work_keys_str_mv | AT hongming cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds AT tanhoryue cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds AT lisha cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds AT cheungfan cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds AT wangning cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds AT nagamatsutadashi cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds AT fengyibin cancerstemcellsthepotentialtargetsofchinesemedicinesandtheiractivecompounds |